Business Context and Reporting Period
This Form 8-K Current Report, dated September 16, 2026, details a material definitive agreement entered into by Teva Pharmaceutical Industries Limited (Teva). The filing reports the issuance of new senior notes by wholly-owned subsidiaries and the simultaneous announcement of conditional redemptions for existing debt instruments.
Key Financial Metrics and Debt Structure
Teva executed a significant refinancing transaction involving the issuance of €1.5 billion in Euro-denominated notes and $3.2 billion in USD-denominated notes. The specific terms are as follows:
- 2033 Euro Notes: €1,000,000,000 principal at 4.250% interest.
- 2036 Euro Notes: €500,000,000 principal at 4.625% interest.
- 2032 USD Notes: $1,200,000,000 principal at 5.250% interest.
- 2034 USD Notes: $1,000,000,000 principal at 5.500% interest.
- 2037 USD Notes: $1,000,000,000 principal at 5.750% interest.
The notes are senior unsecured obligations guaranteed by Teva. The filing does not provide specific revenue, profit, cash flow, or margin data for the reporting period, as this is a transactional filing rather than a periodic financial report.
Material Changes and Debt Refinancing
The primary material change is the restructuring of Teva's debt portfolio. Net proceeds from the new issuances are designated to fund the redemption of existing notes ("Conditional Redemptions"), pay transaction fees, and cover general corporate purposes. Teva intends to redeem the following existing instruments:
- 100% of 6.750% Senior Notes due 2028.
- 100% of 7.875% Sustainability-Linked Senior Notes due 2029.
- 100% of 7.375% Sustainability-Linked Senior Notes due 2029.
- 100% of 8.125% USD Sustainability-Linked Senior Notes due 2031.
- Up to $450,000,000 of 4.750% Sustainability-Linked Senior Notes due 2027.
- Up to €1,150,000,000 of 4.375% Sustainability-Linked Senior Notes due 2030 (reduced from an initial €1.25 billion notice).
This action replaces higher-coupon debt (ranging from 6.750% to 8.125%) with new debt carrying lower interest rates (ranging from 4.250% to 5.750%), likely reducing future interest expense.
Guidance, Risks, and Covenants
The filing does not contain forward-looking guidance on revenue or earnings. However, it outlines specific contractual risks and covenants:
- Redemption Terms: The new notes may be redeemed at the issuer's discretion with 10 to 60 days' notice. Redemption prices are generally the greater of 100% of principal or the present value of remaining payments discounted at specific rates, plus accrued interest.
- Change of Control: The indentures include a make-whole provision requiring an offer to repurchase notes at 101% of principal plus accrued interest upon a change of control.
- Covenants: The agreements limit the Company's ability to create liens on certain property, enter into sale-leaseback transactions, or merge/sell substantially all assets without consent.
- Events of Default: Standard defaults include nonpayment, breach of covenants, acceleration of other debt, and bankruptcy.
Investor Verification Checklist
- Verify the final closing date and actual net proceeds received after deducting underwriting fees and expenses.
- Confirm the final principal amounts redeemed for the "up to" tranches (specifically the 2027 USD notes and 2030 Euro notes) once the conditional redemption period concludes.
- Review the impact of the new interest rates on the company's weighted average cost of debt and future interest coverage ratios.
- Assess the liquidity position of the company to ensure it can meet the redemption obligations for the existing notes if the conditional redemptions are executed.